SG10201407504YA - Pharmaceutical compositions comprising sigma receptor ligands - Google Patents
Pharmaceutical compositions comprising sigma receptor ligandsInfo
- Publication number
- SG10201407504YA SG10201407504YA SG10201407504YA SG10201407504YA SG10201407504YA SG 10201407504Y A SG10201407504Y A SG 10201407504YA SG 10201407504Y A SG10201407504Y A SG 10201407504YA SG 10201407504Y A SG10201407504Y A SG 10201407504YA SG 10201407504Y A SG10201407504Y A SG 10201407504YA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical compositions
- receptor ligands
- sigma receptor
- pharmaceutically acceptable
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09382261A EP2335688A1 (de) | 2009-11-25 | 2009-11-25 | Pharmazeutische Zusammensetzungen, die Sigmarezeptorliganden umfassen |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201407504YA true SG10201407504YA (en) | 2014-12-30 |
Family
ID=42077699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201407504YA SG10201407504YA (en) | 2009-11-25 | 2010-11-25 | Pharmaceutical compositions comprising sigma receptor ligands |
Country Status (33)
Country | Link |
---|---|
US (1) | US9241927B2 (de) |
EP (2) | EP2335688A1 (de) |
JP (1) | JP5827236B2 (de) |
KR (1) | KR101794579B1 (de) |
CN (2) | CN102711736A (de) |
AR (1) | AR079199A1 (de) |
AU (1) | AU2010323097B2 (de) |
BR (1) | BR112012012457A2 (de) |
CA (1) | CA2781726C (de) |
CO (1) | CO6501134A2 (de) |
CY (1) | CY1119357T1 (de) |
DK (1) | DK2503994T3 (de) |
EC (1) | ECSP12011958A (de) |
ES (1) | ES2641637T3 (de) |
HR (1) | HRP20171448T1 (de) |
HU (1) | HUE036377T2 (de) |
IL (1) | IL219996A (de) |
LT (1) | LT2503994T (de) |
MA (1) | MA33836B1 (de) |
ME (1) | ME02876B (de) |
MX (1) | MX351570B (de) |
NZ (1) | NZ600231A (de) |
PL (2) | PL2503993T3 (de) |
PT (1) | PT2503994T (de) |
RS (1) | RS56382B1 (de) |
RU (1) | RU2549882C2 (de) |
SG (1) | SG10201407504YA (de) |
SI (1) | SI2503994T1 (de) |
TN (1) | TN2012000246A1 (de) |
TW (1) | TWI526207B (de) |
UA (2) | UA109421C2 (de) |
WO (1) | WO2011064296A1 (de) |
ZA (1) | ZA201203774B (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2116539A1 (de) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
DK2503993T3 (en) * | 2009-11-25 | 2016-08-22 | Esteve Labor Dr | Hydrochloridsalt af 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]-morpholin |
EP2353598A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Anwendung in der Vorbeugung und/oder Behandlung von postoperativem Schmerz |
EP2353591A1 (de) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Verstärkung der analgesischen Wirkung von Opioden und Opiaten bei postoperativem Schmerz und zur Schwächung der Abhängigkeit davon |
EP2388005A1 (de) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma-Liganden zur Vorbeugung und/oder Behandlung von Erbrechen infolge von Chemotherapie oder Strahlentherapie |
EP2415471A1 (de) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei opioidinduzierter Hyperalgesie |
EP2426111A1 (de) * | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | Feste 4-[-2-[[5-Methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholinhydrochlorid-Formen |
EP2524694A1 (de) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Verwendung von Sigmaliganden bei Schmerz im Zusammenhang mit Typ-2-Diabetes |
WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
EP2792352A1 (de) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2-Adrenorezeptor und Sigmarezeptor-Ligande enthaltenden Kombinationen |
MA39147B1 (fr) | 2013-12-17 | 2019-12-31 | Esteve Labor Dr | Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma |
TN2016000229A1 (en) | 2013-12-17 | 2017-10-06 | Esteve Labor Dr | Gabapentinoids and sigma receptor ligands combinations. |
EP2929883A1 (de) * | 2014-04-08 | 2015-10-14 | Institut Pasteur | Pyrazolderivate als Dihydroorotat-Dehydrogenase-(DHODH)-Hemmer |
MA41177A (fr) * | 2014-12-15 | 2017-10-24 | Esteve Labor Dr | Utilisation de ligands des récepteurs sigma dans l'arthrose |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
EP4124338A1 (de) | 2021-07-30 | 2023-02-01 | Université de Montpellier | Sigma-1-rezeptor-aktivator zur verwendung in der behandlung einer pathologie im zusammenhang mit wfs1-mutation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101352012B1 (ko) * | 2004-08-27 | 2014-01-15 | 라보라토리오스 델 드라. 에스테브.에스.에이. | 시그마 수용체 저해제 |
EP1634872A1 (de) * | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Pyrazolderivate als Inhibitoren von Sigmarezeptoren |
DK1781618T3 (da) * | 2004-08-27 | 2012-10-29 | Esteve Labor Dr | Sigma-receptorinhibitorer |
EP2116539A1 (de) * | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-Aryl-3-Amino-alkoxy-pyrazole als Sigma-Liganden zur Verbesserung der analgetischen Wirkung von Opioiden und zur Schwächung der Abhängigkeit davon |
-
2009
- 2009-11-25 EP EP09382261A patent/EP2335688A1/de not_active Withdrawn
-
2010
- 2010-11-25 PL PL10782303T patent/PL2503993T3/pl unknown
- 2010-11-25 SG SG10201407504YA patent/SG10201407504YA/en unknown
- 2010-11-25 JP JP2012540427A patent/JP5827236B2/ja not_active Expired - Fee Related
- 2010-11-25 LT LTEP10787354.9T patent/LT2503994T/lt unknown
- 2010-11-25 EP EP10787354.9A patent/EP2503994B1/de active Active
- 2010-11-25 BR BR112012012457-9A patent/BR112012012457A2/pt not_active IP Right Cessation
- 2010-11-25 PL PL10787354T patent/PL2503994T3/pl unknown
- 2010-11-25 TW TW099140790A patent/TWI526207B/zh not_active IP Right Cessation
- 2010-11-25 HU HUE10787354A patent/HUE036377T2/hu unknown
- 2010-11-25 AU AU2010323097A patent/AU2010323097B2/en not_active Ceased
- 2010-11-25 SI SI201031545T patent/SI2503994T1/sl unknown
- 2010-11-25 KR KR1020127016395A patent/KR101794579B1/ko active IP Right Grant
- 2010-11-25 CN CN2010800608515A patent/CN102711736A/zh active Pending
- 2010-11-25 DK DK10787354.9T patent/DK2503994T3/en active
- 2010-11-25 RS RS20170948A patent/RS56382B1/sr unknown
- 2010-11-25 NZ NZ600231A patent/NZ600231A/xx not_active IP Right Cessation
- 2010-11-25 CA CA2781726A patent/CA2781726C/en not_active Expired - Fee Related
- 2010-11-25 ME MEP-2017-230A patent/ME02876B/de unknown
- 2010-11-25 UA UAA201207655A patent/UA109421C2/ru unknown
- 2010-11-25 US US13/511,706 patent/US9241927B2/en not_active Expired - Fee Related
- 2010-11-25 MX MX2012006106A patent/MX351570B/es active IP Right Grant
- 2010-11-25 UA UAA201207654A patent/UA112055C2/uk unknown
- 2010-11-25 WO PCT/EP2010/068213 patent/WO2011064296A1/en active Application Filing
- 2010-11-25 CN CN201610049373.7A patent/CN105560250A/zh active Pending
- 2010-11-25 ES ES10787354.9T patent/ES2641637T3/es active Active
- 2010-11-25 PT PT107873549T patent/PT2503994T/pt unknown
- 2010-11-25 RU RU2012126126/04A patent/RU2549882C2/ru not_active IP Right Cessation
- 2010-11-25 AR ARP100104369A patent/AR079199A1/es unknown
-
2012
- 2012-05-22 TN TNP2012000246A patent/TN2012000246A1/en unknown
- 2012-05-23 ZA ZA2012/03774A patent/ZA201203774B/en unknown
- 2012-05-24 IL IL219996A patent/IL219996A/en not_active IP Right Cessation
- 2012-06-08 EC ECSP12011958 patent/ECSP12011958A/es unknown
- 2012-06-20 MA MA34987A patent/MA33836B1/fr unknown
- 2012-06-25 CO CO12106020A patent/CO6501134A2/es unknown
-
2017
- 2017-09-18 CY CY20171100982T patent/CY1119357T1/el unknown
- 2017-09-26 HR HRP20171448TT patent/HRP20171448T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2012000246A1 (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
CA2757418C (en) | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same | |
UA105766C2 (uk) | Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин | |
WO2010136474A3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
MX2011010415A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
MX2014000341A (es) | Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades. | |
MY151003A (en) | Stable pharmaceutical composition comprising a pyrimidine-sulfamide | |
AR088195A1 (es) | Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida | |
TN2013000257A1 (en) | Immunosuppressant formulations | |
MY151295A (en) | Pyrimidyl indoline compound | |
MX2013004162A (es) | Composiciones farmaceuticas que contienen un inhibidor de dgat1. | |
UA116334C2 (uk) | Тверді форми дозування бендамустину | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
WO2011025982A3 (en) | Tetracycline compounds | |
RS20110136A1 (en) | PREPARATIONS CONTAINING AMLODIPINE AND BIZOPROLOL | |
UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
MX2009008039A (es) | Gamma lactamas substituidas como agentes terapeuticos. | |
TN2010000120A1 (en) | Galenical formulations of organic compounds | |
MX342824B (es) | Nuevos compuestos de triazol iii. | |
MX2010013978A (es) | Derivados de 5-(4-metanosulfonilfenil)tiazol para el tratamiento de enfermedades inflamatorias agudas y cronicas. | |
TR200802061A2 (tr) | Yüksek oranda aktif madde içeren farmasötlk formülasyon. | |
IN2014DN07898A (de) | ||
WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate | |
TN2013000137A1 (en) | Pharmaceutical compositions containing a dgat 1 inhibitor | |
TH118221B (th) | สูตรผสมกาเลนนิคัสของสารประกอบอินทรีย์ |